Global circulating Tumor Cells Market: Snapshot

The global circulating tumor cells prognostic technologies market are rising in demand due to increasing demand for diagnostic technologies. This rise in demand for these technologies are primarily due to prevalence rate of cancer. Huge application scope of these technologies are dependent on safety of patients. Substantial Rise in therapeutic monitoring is rising the demand for the market. Increased death rates due to development of metastases and hematogenous dissemination of cancer is also boosting the need for detection of circulating tumor cells. Novel technologies for detection of circulating tumor cells are rising in demand due to many clinical trials including them as their secondary end points and in their translation research programs. The global market is expecting wider implementation possibilities of circulating tumor cells prognostic technologies in the coming years due to increasing rate of research and development activities conducted for developing personalized medicines.

According to a report by Transparency Market Research, the global circulating tumor cells prognostic technologies market is anticipated to rise at a tremendous CAGR of 26.30% during the forecast period of 2014 to 2020. The global market value is expected to attain a valuation of US$2.16 bn by the end of the forecast period.

Rise in Breast Cancer to Supplement Application of Technology with CAGR of 27.10% by 2020

The global circulating tumor cells prognostic technologies market have been segmented according to technology and applications. Technology segment is further sub segmented into tumor cell enrichment and tumor cell detection. The tumor cell detection segment is further bifurcated into molecular method and optical method. Among these, optical method segment is anticipated to rise at a rising CAGR of 27.30% during the forecast period of 2014 to 2020. The tumor cell enrichment is further sub segmented into immunomagnetic method and immunological method, centrifugation, and filtration. Among these sub segments, immunomagnetic method will account for the largest share in the tumor cell enrichment segment.

The global circulating tumor cells prognostic technologies by application is segmented into prostate cancer, breast cancer, colorectal cancer, pancreatic cancer, lung cancer, and ovarian cancer. Among these sub segments, prostate cancer is expected to rise at a significant CAGR of 25.20% during forecast period whereas, the breast cancer segment is anticipated to reach 27.10% CAGR by the end of 2020. Rise in breast cancer is accounting for a significant share in the market and is expected to rise in the coming years.

Increasing Prognostic Technologies to Boost North America Market

The global circulating tumor cells prognostic technologies market is spread across various regions such as North America, Asia pacific, Europe, and the rest of the world. Among these, North America is holding the largest shares in the market due to increased incidence and prevalence of cancer. The market in this region is also dominating the market due to increased adoption rate of advanced prognostic technologies. North America has disposable income that people are willing to spend on healthcare thus, it boosts the market in this region. Government’s extensive support for research and development in this region is supplementing the market growth of North America.

Similarly, Asia Pacific is also experiencing significant growth rate in the market. This region is experiencing steady growth in the market due to rise in various types of cancers among the people. The key players and government of various countries in this region is encouraging research and development activities to produce better technologies. Innovations have led to increased adoption rate of advanced therapeutic monitoring technologies in this region. Rise in population has resulted in rise of different types of cancer. Emerging economies in this region are showing potential rise in advancement and implication of the technologies.

Some of the key players operating in the circulating tumor cells prognostic technologies market are Epic Science, Silicon Biosystems, Vitatex, Veridex, and AVIVA Biosciences Corp.

This report provides the market analysis for various technologies and applications used for the enrichment and detection of circulating tumor cells (CTCs). The stakeholders of this report include companies and research institutes involved in the production of prognosis kits and research and development activities related to circulating tumor cells technologies as well as the new entrants who wish to enter this market.
 
The market overview section of the report analyzes the market dynamics and trends such as drivers, restraints and opportunities that would affect the current and future scenario of the CTC technologies market. Porter’s five forces analysis is included in this study to provide thorough analysis about the competitive status, and market attractiveness analysis has been added to describe the market outlook in different geographies. Event impact analysis is provided in this report for a brief understanding of the technological advancements that have taken place in the past and are planned for the future. Value chain analysis of the market is discussed to recognize value-creating activities from a number of processes, which can provide CTC technology a competitive advantage over other technologies.
 
Circulating tumor cells (CTCs) are specialized rare cells detached from primary tumors and disseminated in the vasculature system of the body, eventually causing metastasis. CTCs are composed of cells that act as seeds for successive development of additional metastatic tumors in essential distant organs, which is a cause of majority of cancer-related deaths. These CTCs are not easily detected, as these are present in less numbers in the blood stream. Tumors shed nearly 1 million circulating tumor cells (CTCs) per gram of tumor tissue. The global circulating tumor cells (CTCs) prognostic technologies market is segmented based on technologies and applications. Moreover, the technology market is further segmented into tumor cell enrichment and tumor cell detection. 
 
Based on tumor cell enrichment technologies, the report includes market analysis of filtration, centrifugation and immunological & immunomagnetic enrichment methods. Based on tumor cell detection technologies, the market is segmented into molecular methods and optical methods. Furthermore, based on the applications, the CTC prognostic technologies market is segmented into breast cancer, colorectal cancer, prostate cancer and others (lung, ovarian and pancreatic cancer). Market forecast for all these segments has been provided in the report for the period 2012 to 2020 in terms of USD million, along with CAGR for the forecast period 2014 to 2020, considering 2013 as the base year.
 
Geographically, the global CTCs prognostic technologies market has been segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). North America is the leading market for CTCs prognostic technologies owing to the high adoption rate for advanced prognostic technologies as well as high prevalence and incidence rate of cancer. However, low commercial availability of these technologies and stringent regulatory approvals of these technologies are some of the factors that have led to the sluggish growth of this market. However, other regions such as Asia-Pacific is also expected to show a substantial growth rate owing to the increasing base of cancer patients coupled with high government support and growing adoption rate for advanced therapeutic monitoring technologies. The market revenue of CTC technologies for 2012 and 2020 and forecast from 2014 to 2020 in respective regions in terms of USD million and value percentage, respectively, is explained in this section of the report.
 
The report concludes with the profiles of key players in the CTC technologies market. Major companies profiled in this report include AdnaGen AG, Advanced Cell Diagnostics, Inc., AVIVA BioSciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc., Silicon Biosystems, S.p.A., Veridex, LLC, Vitatex, Inc. and others.
 
The global circulating tumor cells (CTCs) prognostic technologies market is segmented as follows:
  • Circulating Tumor Cells (CTCs) Prognostic Technologies Market, by Technology
    • Tumor Cell Enrichment
      • Filtration
      • Centrifugation
      • Immunological & Immunomagnetic Methods
    • Tumor Cell Detection
      • Molecular Methods
      • Optical Methods
  • Circulating Tumor Cells (CTCs) Prognostic Technologies Market, by Applications
    • Prostate Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Others (Lung, Ovarian and Pancreatic Cancer)

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

 
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global CTCs Prognostic Technologies Market
2.2 Comparative Analysis: Global CTCs Prognostic Technologies Market, by Geography, 2013 & 2020 (Value %)
 
Chapter 3 Global CTCs Prognostic Technologies Market Overview
3.1 Market Dynamics and Overview
3.1 Market Drivers
      3.1.1 Escalating Prevalence Rate of Cancer
      3.1.2 High Cost-benefit Ratio
      3.1.3 Increased Evaluation of Therapeutic Monitoring
      3.1.4 Technological Development
3.2 Market Restraints
      3.2.1 High Pricing Associated with CTCs Detection
      3.2.2 Lack of Specificity and Sensitivity
      3.2.3 Reluctance in Adopting Advanced Prognostic Technologies 
3.3 Market Opportunities
      3.3.1 Strengthening Distribution Network In Emerging Markets
      3.3.2 Development of Personalized Medicines based on CTCs
3.4 Porter’s Five Forces Analysis
      3.4.1 Bargaining Power of Suppliers
      3.4.2 Bargaining Power of Buyers
      3.4.3 Threat of Substitutes
      3.4.4 Threat of New Entrants
      3.4.5 Competitive Rivalry
3.5 Event Impact Analysis (Historical Trends and Future Outlook), 2012 – 2020
3.6 Market Attractiveness Analysis of Global CTCs Prognostic Technologies Market, by Geography
3.7 Competitive Landscape
      3.7.1 Global Market Share Analysis, by Key Players, Global CTCs Prognostic Technologies Market, 2013 (Value %)
 
Chapter 4 Global CTCs Prognostic Technologies Market, by Technology
4.1 Overview
4.2 Tumor Cell Enrichment
      4.2.1 Global Tumor Cell Enrichment Market Revenue, 2012 – 2020 (USD Million)
      4.2.2 Filtration
               4.2.2.1 Global Tumor Cell Enrichment by Filtration Market Revenue, 2012 – 2020 (USD Million)
      4.2.3 Centrifugation
               4.2.3.1 Global Tumor Cell Enrichment by Centrifugation Market Revenue, 2012 – 2020 (USD Million)
      4.2.4 Immunological and Immunomagnetic Methods
               4.2.4.1 Global Tumor Cell Enrichment by Immunological and Immunomagnetic Methods Market Revenue, 2012 – 2020 (USD Million)
4.3 Tumor Cell Detection
      4.3.1 Global Tumor Cell Detection Market Revenue, 2012 – 2020 (USD Million)
      4.3.2 Molecular Methods
               4.3.2.1 Global Tumor Cell Detection by Molecular Methods Market Revenue, 2012 – 2020 (USD Million)
      4.3.3 Optical Methods
               4.3.3.1 Global Tumor Cell Detection by Optical Methods Market Revenue, 2012 – 2020 (USD Million)
 
Chapter 5 Global CTCs Prognostic Technologies Market, by Applications
5.1 Overview
      5.1.1 Global CTCs Prognostic Technologies Market Revenue, by Applications, 2012 – 2020 (USD Million)
5.2 Prostate Cancer
      5.2.1 Global CTCs Application in Prostate Cancer Market Revenue, 2012 – 2020 (USD Million)
5.3 Breast Cancer
      5.3.1 Global CTCs Application in Breast Cancer Market Revenue, 2012 – 2020 (USD Million)
5.4 Colorectal Cancer
      5.4.1 Global CTCs Application in Colorectal Cancer Market Revenue, 2012 – 2020 (USD Million)
5.5 Others (Lung Cancer, Ovarian Cancer and Pancreatic Cancer)
      5.5.1 Global CTCs Application in Other Cancer Types Market Revenue, 2012 – 2020 (USD Million)
 
Chapter 6 Global CTCs Prognostic Technologies Market, by Geography
6.1 Overview
      6.1.1 Global CTCs Prognostic Technologies Market Revenue, by Geography, 2012 – 2020 (USD Million)
6.2 North America
      6.2.1 North America CTCs Prognostic Technologies Market Revenue, 2012 – 2020 (USD Million)
6.3 Europe
      6.3.1 Europe CTCs Prognostic Technologies Market Revenue, 2012 – 2020 (USD Million)
6.4 Asia-Pacific
      6.4.1 Asia-Pacific CTCs Prognostic Technologies Market Revenue, 2012 – 2020 (USD Million)
6.5 Rest of the World (RoW)
      6.5.1 RoW CTCs Prognostic Technologies Market Revenue, 2012 – 2020 (USD Million)
 
Chapter 7 Recommendations
 
Chapter 8 Company Profiles
8.1 AdnaGen GmbH
      8.1.1 Company Overview
      8.1.2 Financial Overview
      8.1.3 Product Portfolio
      8.1.4 Business Strategies
      8.1.5 Recent Developments
8.2 Advanced Cell Diagnostics, Inc.
      8.2.1 Company Overview
      8.2.2 Financial Overview
      8.2.3 Product Portfolio
      8.2.4 Business Strategies
      8.2.5 Recent Developments
8.3 AVIVA Biosciences Corporation
      8.3.1 Company Overview
      8.3.2 Financial Overview
      8.3.3 Product Portfolio
      8.3.4 Business Strategies
8.4 Celula, Inc.
      8.4.1 Company Overview
      8.4.2 Financial Overview
      8.4.3 Product Portfolio
      8.4.4 Business Strategies
8.5 Epic Sciences, Inc.
      8.5.1 Company Overview
      8.5.2 Financial Overview
      8.5.3 Product Portfolio
      8.5.4 Business Strategies
      8.5.5 Recent Developments
8.6 Fluxion Biosciences, Inc.
      8.6.1 Company Overview
      8.6.2 Financial Overview
      8.6.3 Product Portfolio
      8.6.4 Business Strategies
      8.6.5 Recent Developments
8.7 Rarecells USA, Inc.
      8.7.1 Company Overview
      8.7.2 Financial Overview
      8.7.3 Product Portfolio
      8.7.4 Business Strategies
8.8 Silicon Biosystems, S.p.A.
      8.8.1 Company Overview
      8.8.2 Financial Overview
      8.8.3 Product Portfolio
      8.8.4 Business Strategies
      8.8.5 Recent Developments
8.9 Vitatex, Inc.
      8.9.1 Company Overview
      8.9.2 Financial Overview
      8.9.3 Product Portfolio
      8.9.4 Business Strategies
8.10 Veridex, LLC
      8.10.1 Company Overview
      8.10.2 Financial Overview
      8.10.3 Product Portfolio
      8.10.4 Business Strategies
      8.10.5 Recent Developments
List of Tables
 
TABLE 1 Market Snapshot: Global CTCs Prognostic Technologies Market
TABLE 2 Global CTCs Prognostic Technologies Market Revenue, by Technology, 2012 – 2020 (USD Million)
TABLE 3 Global Tumor Cell Enrichment Market Revenue, 2012 – 2020 (USD Million)
TABLE 4 Global Tumor Cell Detection Market Revenue, 2012 – 2020 (USD Million)
TABLE 5 Global CTCs Prognostic Technologies Market Revenue, by Applications, 2012 – 2020 (USD Million)
TABLE 6 Global CTCs Prognostic Technologies Market Revenue, by Geography, 2012 – 2020 (USD Million)
List of Figures
 
FIG. 1 CTCs Prognostic Technologies: Market Segmentation
FIG. 2 Global CTCs Prognostic Technologies Market, by Technology, 2012 (USD Million)
FIG. 3 Global CTCs Prognostic Technologies Market, by Applications, 2012 (USD Million)
FIG. 4 Comparative Analysis: CTCs Prognostic Technologies Market, by Geography, 2013 & 2020 (Value %)
FIG. 5 Circulating Tumor Cells (CTCs) Prognostic Technologies Market: Drivers and Restraints
FIG. 6 Porter’s Five Forces Analysis: Circulating Tumor Cells (CTCs) Prognostic Technologies Market
FIG. 7 Market Attractiveness Analysis: Global CTCs Prognostic Technologies Market, by Geography
FIG. 8 Market Share by Key Players: Global CTCs Prognostic Technologies Market, 2013 (Value %)
FIG. 9 Global Tumor Cell Enrichment by Filtration Market Revenue, 2012 – 2020 (USD Million)
FIG. 10 Global Tumor Cell Enrichment by Centrifugation Market Revenue, 2012 – 2020 (USD Million)
FIG. 11 Global Tumor Cell Enrichment by Immunological and Immunomagnetic Methods Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 Global Tumor Cell Detection by Molecular Methods Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 Global Tumor Cell Detection by Optical Methods Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Global CTCs Application in Prostate Cancer Market Revenue, 2012 – 2020 (USD Million)
FIG. 15 Global CTCs Application in Breast Cancer Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 Global CTCs Application in Colorectal Cancer Market Revenue, 2012 – 2020 (USD Million)
FIG. 17 Global CTCs Application in Other Cancer Types Market Revenue, 2012 – 2020 (USD Million)
FIG. 18 North America CTCs Prognostic Technologies Market Revenue, 2012 – 2020 (USD Million)
FIG. 19 Europe CTCs Prognostic Technologies Market Revenue, 2012 – 2020 (USD Million)
FIG. 20 Asia-Pacific CTCs Prognostic Technologies Market Revenue, 2012 – 2020 (USD Million)
FIG. 21 RoW CTCs Prognostic Technologies Market Revenue, 2012 – 2020 (USD Million)
FIG. 22 Alere, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 23 Menarini Group: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 24 Johnson & Johnson: Annual Revenue, 2011 – 2013 (USD Million)

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Ctcs Prognostic Technologies Market